# Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

> **NCT01226420** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 6 (actual)

## Conditions studied

- Chronic Graft-versus-host Disease

## Interventions

- **DRUG:** Alefacept

## Key facts

- **NCT ID:** NCT01226420
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Discontinuation of drug supply from Astellas.
- **Last updated:** 2013-08-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226420, "Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01226420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*